A new series of eight first-and second-generation heterometallic ferrocenyl-derived metal-arene metallodendrimers, containing ruthenium(II)-p-cymene, ruthenium(II)-hexamethylbenzene, rhodium(III)-cyclopentadienyl or iridium(III)-cyclopentadienyl moieties have been prepared. The metallodendrimers were synthesized by first reacting DAB-(NH 2 ) n (where n = 4 or 8, DAB = diaminobutane) with salicylaldehyde, and then the Schiff-base dendritic ligands were reacted in a one-pot reaction with the appropriate 
Introduction
Research on the design of heterometallic complexes as possible anticancer agents has flourished. [1] [2] [3] [4] [5] [6] Due to its favourable electronic properties and ease of functionalization, [7] [8] [9] [10] [11] [12] ferrocene has been incorporated in various biologically active systems, 9, 13, 14 in an effort to achieve a synergistic effect between the metal centers. [15] [16] [17] [18] [19] [20] Furthermore, simple derivatives of ferrocene display good activity in vitro, with inhibition of tumors observed in vivo. 21, 22 In the search for new tamoxifen-like drugs, Jaouen and co-workers 23, 24 prepared ferrocifens from 1-[4-(2-dimethylaminoethoxy)]-1-( phenyl-2-ferrocenylbut-1-ene), which are highly active ferrocenyl-derivatives of the purely organic breast cancer drug tamoxifen. The increase in activity is attributed to the dual action of the organic drug and the Fenton chemistry (i.e. formation of singlet oxygen) of the Fe centre. 25, 26 Moreover, the stability of ferrocene in aqueous and aerobic media, the facility with which a large variety of derivatives may be prepared, and its favorable electrochemical properties, has resulted in ferrocene becoming a promising molecule for incorporating in biological applications. 12 Furthermore, certain ferrocene-containing compounds exhibit cytotoxicities comparable to the benchmark anticancer drug, cisplatin. Due to the undesirable side-effects displayed by platinumbased anticancer drugs, 27, 28 researchers have turned their attention to other metals. 29, 30 One such metal is ruthenium, as ruthenium complexes tend to be less cytotoxic in comparison to platinum compounds, 31 and two promising Ru(III) anticancer agents are undergoing clinical trials. [32] [33] [34] [35] The activity of the Ru(III) anticancer agents is thought to be brought about by reduction of the compounds to a Ru(II) species in vivo, 33 and consequently there is a growing interest in the preparation and biological evaluation of ruthenium(II)-arene complexes. [36] [37] [38] [39] [40] [41] [42] Two anticancer agents are at the forefront of this promising class of organometallic compounds, RAED-C [(η 6 -p-cym)Ru (ethylene-diamine)Cl]PF 6 , 43, 44 and RAPTA-C [(η 6 -p-cym)Ru
(1,3,5-triaza-7-phosphaadamantane)Cl 2 ]. 45, 46 The former is a cytotoxic compound that binds preferentially to DNA, 47 whereas the latter is a non-cytotoxic antitumor compound, 46, [48] [49] [50] [51] that displays an antiangiogenic effect 52 and binds preferentially to histone proteins. 47, 49 In addition, a host of Rh(III)-Cp* and Ir(III)-Cp* (where Cp* = cyclopentadienyl) derivatives have previously demonstrated pharmacological properties, [53] [54] [55] [56] [57] [58] which promote further study of these compounds.
The concept of combining organometallic complexes with compounds of known therapeutic value is a growing area of research, and coupled with the notion of multinuclearity that can result in enhanced therapeutic activity, 19, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] the combination is an attractive drug-design strategy. Moreover, one way of introducing the notion of multinuclearity is to conjugate therapeutic agents onto dendritic scaffolds, 59, [72] [73] [74] [75] [76] [77] that could potentially exploit the enhanced permeability and retention (EPR) effect. [78] [79] [80] Recently, we reported tetranuclear and octanuclear N,Oand N,N-ruthenium-arene metallodendrimers, with ferrocene moieties functionalized on the periphery of the dendritic scaffold. The majority of the compounds efficiently inhibit the growth of both A2780 cisplatin-sensitive and A2780cisR cisplatin-resistant human ovarian cancer cells (i.e. IC 50 < 5 μM). 81 In addition, these complexes displayed no cross-resistance to cisplatin, with the metallodendrimers having a better activity compared to their mononuclear complexes. On the basis of the above observed results we hypothesized that preparing ferrocenyl-derived metal-arene metallodendrimers, where the ferrocenyl moiety is coordinated directly to the metal center rather than on the periphery, may further enhance the antiproliferative activity of the compounds. In this study, we describe the synthesis of a series of bidentate heterometallic ferrocenyl-derived dendrimers containing ruthenium(II)-p-cymene, ruthenium(II)-HMB (where HMB = hexamethylbenzene), rhodium(III)-Cp* or iridium(III)-Cp* (where Cp* = cyclopentadienyl) moieties [1] Scheme 1) . The cytotoxicity of the complexes was evaluated against the A2780 and the A2780cisR human ovarian cancer cell lines, as well as against the non-cancerous human embryonic kidney (HEK-293) cell line. In order to investigate whether the antiproliferative activity is size-dependent, binuclear model analogues [9] [PF 6 ]- [12] [PF 6 ] were also prepared and evaluated. were reacted with one equivalent of the particular metaldimer, in the presence of triethylamine, in a one-pot reaction (Scheme 2). Subsequently, 4-ferrocenylpyridine was added to the reaction mixture, which generated a cationic complex, and the products were isolated as red or red-orange hexafluorophosphate salts. [4][PF 6 ] 8 (4.7 μM in A2780; 3.5 μM in A2780cisR), [6] [PF 6 ] 8 (11.7 μM in A2780; 7.6 μM in A2780cisR) and [8] 8 was observed compared to their neutral Ru-HMB-Cl analogs (G1-Ru-HMB-Cl = 27 μM (A2780); 25 μM (A2780cisR); G2-Ru-HMB-Cl = 10 μM (A2780); 10 μM (A2780cisR)) reported previously, 83 with comparable activities to their cationic Ru-HMB-PTA analogs (G1-Ru-HMB-PTA = 9 μM (A2780); 25 μM (A2780cisR); G2-Ru-HMB-PTA = 6 μM (A2780); 12 μM (A2780cisR)). 73 There is a correlation between the size-dependency of the metallodendrimers and the cytotoxicity, with metallodendrimers [3] (ferrocene at the metal center) and the previously prepared systems (ferrocene at the periphery) 81 cannot be made as different in vitro biological studies were performed. However, coordination of the pyridylferrocene moiety to the Ru center affords more cytotoxic compounds.
Results and discussion

NMR stability study
Compound stability is important for biological applications and, in the case of metal-based drugs, many compounds are actually prodrugs and hence the identity of the compound that reaches the cell can be important. Following uptake into the cell, related ruthenium-arene-PTA complexes are activated via aquation, generating the aqua species, a process that can be monitored by NMR spectroscopy. 85 (Fig. 1) show that the compounds are stable in solution, with no side-products or the formation of the aqua-species observed over a period of 24 hours. In addition, these data show that the complexes are stable in deuterated dimethylsulfoxide, relevant during the time period between preparation of the compound stock solutions and dosing of the cancer cells in the assay. 
UV-Vis study: interactions with a DNA model
DNA is a potential drug target for ruthenium-arene compounds and is an important target in cancer therapy. 87 Furthermore, some of the most cytotoxic ruthenium drugs act as DNA intercalators upon coordination to the suitable ancillary ligand. 40 In order to correlate the antiproliferative activity of the metallodendrimers to possible interactions with DNA, a UV-vis study was performed. 6 ] display hypochromic shifts (upon DNA addition) as the absorbance at λ max = 320 nm (for [4] [PF 6 ] 8 ) and λ max = 310 nm (for [10] [PF 6 ]) decrease, with no substantial red-or blue-shift observed for λ max for both systems (Fig. 2) . Similar hypochromic shifts were reported with Cu(II), Co(II) and Ni(II) complexes upon addition of increasing concentration of DNA, 88 whereas norepinephrine (DNA binding agent) displays a hyperchromic shift upon DNA addition. 89 A hyperchromic shift is usually associated with the partial uncoiling of the DNA double helix, which exposes more of the DNA base-pairs, which in turn results in the increase in absorbance at λ max . However, hypochromic effects are also associated with non-covalent interactions between the complex and DNA, such as intercalative binding, 90 indicating that DNA could be a relevant target for these compounds.
Conclusions
A series of bidentate heterometallic ferrocenyl-derived dendrimers containing ruthenium(II)-p-cymene, ruthenium(II)-HMB, rhodium(III)-cyclopentadienyl or iridium(III)-cyclopentadienyl moieties have been successfully synthesized and characterized.
Heterometallic model complexes were also prepared and characterized (for comparison with the larger metallodendrimers). Antiproliferative studies performed on the metallodendrimers and the model binuclear complexes show that the model complexes display limited activity, whereas the metallodendrimers display higher cytotoxicities, particularly the second-generation ferrocenyl-derived ruthenium(II)-hexamethylbenzene metallodendrimer, which displayed the best activity of the series. The presence of ferrocene leads to more cytotoxic compounds compared to previously reported nonferrocenyl derivatives. In addition, these metallodendrimers displayed no cross-resistance to cisplatin and some are cancer cell selective, being less cytotoxic to the non-tumorigenic cells included in the study. Spectroscopic studies illustrate that these systems are stable in solution and additional DNA binding studies suggest that a possible mode-of-action of these metallodendrimers (at least for the most active derivative) involves possible non-covalent interactions (illustrated by UV-vis experiments) with the DNA.
Experimental
General details
All solvents and reagents were purchased from Sigma-Aldrich; DAB-G 2 -PPI-(NH 2 ) 8 16 were prepared according to literature procedures.
Infrared (IR) spectra determined in the solid state on a PerkinElmer Spectrum 100 FT-IR spectrometer equipped with a SMART iTR ATR unit. The intensity of stretching vibrations are marked 
Cytotoxicity studies
The human A2780 and A2780cisR ovarian carcinoma cell lines were obtained from the European Collection of Cell Cultures (Salisbury, UK). Non-tumorigenic HEK-293 cells were obtained from ATCC (Sigma, Switzerland). Cells were grown routinely in RPMI-1640 GlutaMax medium with 10% fetal bovine serum (FBS, Pan Biotech, Germany) and 1% antibiotics at 37°C and 5% CO 2 . Cytotoxicity was determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) as previously described. 83 Briefly, cells were seeded in 96-well plates as monolayers with 100 μL of cell solution (approximately 10 000 cells) per well and pre-incubated for 24 h in medium supplemented with 10% FBS. Compounds were prepared as DMSO solution, then dissolved in the culture medium and immediately serially diluted to the appropriate concentration, to give a final DMSO concentration of 0.5%. A 100 μL portion of drug solution was added to each well and the plates were incubated for another 72 h. Subsequently, MTT (5 mg mL −1 solution in PBS) was added to the cells and the plates were incubated for a further 4 h. The culture medium was aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved in DMSO. The optical density, directly proportional to the number of surviving cells, was quantified at 590 nm using a multiwell plate reader and the fraction of surviving cells was calculated from the absorbance of untreated control cells. The IC 50 values were determined by fitting the plot of the log of the ratio between the percentages of surviving cells, divided by the amount of dead cells, against the log of drug concentration using a linear threshold function. Evaluation is based on means from at least two independent experiments, each comprising four microcultures per concentration level.
NMR studies
For the stability/aquation studies, second generation metallodendrimer [4] 
